Home » Topics » Regulatory » EMA

EMA
RSS

EMA validates Zinbryta MAA for relapsing forms of MS

March 31, 2015

EMA grants orphan drug designation to Reolysin for gynecological cancers

March 25, 2015

EMA grants orphan status to Kamada treatment for graft-versus-host disease

March 25, 2015

Stempeucel receives EMA advanced therapy medicinal product classification

March 24, 2015

NovImmune's HLH trial of NI-0501 allows first-line treatment after protocol amendment

March 19, 2015

ImMucin receives E.U. orphan drug designation for multiple myeloma

March 17, 2015

AOP Orphan completes enrollment in phase III trial of ropeginterferon alfa 2b

March 9, 2015

CHMP recommends approval of Humira for severe chronic plaque psoriasis in children

March 3, 2015

EMA committee recommends approval of Avastin plus chemotherapy for advanced cervical cancer

March 3, 2015

EMA accepts MAA for Santen's intravitreal sirolimus for non-infectious uveitis

March 2, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...